{Reference Type}: Journal Article
{Title}: Efficacy of a specific polyclonal equine F(ab')2 against avian influenza (H5N1) in ferrets: synergy with oseltamivir.
{Author}: Herbreteau CH;Denizot M;Lowther S;Riddell S;Frazer L;Haining J;Arkinstall R;Payne J;Harper J;Johnson D;Pasquier A;Middleton D;Saluzzo JF;
{Journal}: Immunotherapy
{Volume}: 8
{Issue}: 9
{Year}: 09 2016
{Factor}: 4.04
{DOI}: 10.2217/imt-2016-0062
{Abstract}: Current therapies against avian influenza (H5N1) provide limited clinical benefit. FBF-001 is a highly purified equine polyclonal immunoglobulin fragment against H5N1.<BR>Using a ferret model of severe acute H5N1 infection, we assessed FBF-001 when administered on the same day or 1 day after viral challenge, in comparison with oseltamivir therapy.<BR>Untreated animals died 2-3 days after challenge. FBF-001 prevented most severe illness and reduced nasal viral load, with best efficacy when administered on the day of viral challenge. Oseltamivir and FBF-001 had synergistic impact on survival.<BR>FBF-001 prevented severe consequences of lethal H5N1 challenge in ferrets by controlling viral replication, an effect synergistic to oseltamivir. FBF-001 has recently been granted EMA orphan drug status.